Xcout Intel
Renibus Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Renibus Therapeutics, Inc. among drug discovery companies — ranked by similarity to what Renibus Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Renibus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Renibus Therapeutics, Inc.
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Renibus Therapeutics, Inc. at a glance
Renibus Therapeutics, Inc. is a drug discovery company headquartered in United States. Its most recent funding round, Series B, raised $72M in September 2023. Xcout tracks 8 named people at Renibus Therapeutics, Inc., including D Jeffrey Keyser (Chief Executive Officer).
Renibus Therapeutics, Inc. leadership
- D Jeffrey KeyserChief Executive Officer
- D. Jeff KeyserPresident and CEO
- Jamie A. DonadioChief Financial Officer
- Asha RamdasChief Technical Officer
- Bhupinder SinghChief Medical Officer
- HENRIK RASMUSSENChairman
2 more named people on record for Renibus Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Renibus Therapeutics, Inc. funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $72M | — | |
| SEC Form D filing | $110.9M | — | |
| SEC Form D filing | $23.4M | — | |
| SEC Form D filing | $3.4M | — | |
| — | $19.8M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Renibus Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Renibus Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Similar drug discovery company
Rege Nephro Co., Ltd. is a biotechnology company headquartered at Kyoto University in Kyoto, Japan. The company engages in medical-pharmaceutical collaborative research and advanced therapeutic development for kidney and regenerative medicine.
Similar drug discovery company
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Similar drug discovery company
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Similar drug discovery company
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Similar drug discovery company
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Biopharma
Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.
Similar drug discovery company
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Biopharmaceuticals
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Biopharmaceuticals
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, dedicated to advancing therapies to treat rare diseases.
Biopharmaceuticals
JDP Therapeutics, Inc. is a pharmaceutical company with its operations and headquarters located in Lansdale, Pennsylvania, focusing on the development of specialty therapeutics.
Biopharmaceuticals
Cara Therapeutics is a U.S. biopharmaceutical company that develops therapies targeting the peripheral kappa opioid receptor to treat pruritus and other conditions. Its lead product, difelikefalin (marketed as Korsuva in the United States), is approved for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Renibus Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Renibus Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →